Flex Pharma Inc. (FLKS)

3.58
0.13 3.63
NASDAQ : Health Technology
Prev Close 3.71
Open 3.73
Day Low/High 3.50 / 3.73
52 Wk Low/High 3.70 / 24.45
Volume 11.69K
Avg Volume 1.16M
Exchange NASDAQ
Shares Outstanding 18.07M
Market Cap 10.96M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Flex Pharma Announces Broker Authority To Vote On Certain Proposals

Flex Pharma Announces Broker Authority To Vote On Certain Proposals

Flex Pharma, Inc. (Nasdaq: FLKS) today announced that on or about June 27, 2019 it will mail a supplement (the "Supplement") to its proxy materials to provide stockholders with updated information regarding brokers' discretionary authority to vote...

Flex Pharma Announces Overwhelming Support To Date For The Proposed Merger With Salarius Pharmaceuticals But More Votes Are Needed To Complete The Merger

Flex Pharma Announces Overwhelming Support To Date For The Proposed Merger With Salarius Pharmaceuticals But More Votes Are Needed To Complete The Merger

Flex Pharma, Inc. (Nasdaq: FLKS) today announced that approximately 85% of shares voted to date support the proposed merger with Salarius Pharmaceuticals, LLC, an epigenetic oncology company.

Flex Pharma Announces That ISS And Glass Lewis Recommend Shareholders Vote "FOR" All Agenda Items Relating To Flex's Strategic Merger With Salarius Pharmaceuticals

Flex Pharma Announces That ISS And Glass Lewis Recommend Shareholders Vote "FOR" All Agenda Items Relating To Flex's Strategic Merger With Salarius Pharmaceuticals

Flex Pharma, Inc. (Nasdaq: FLKS) today announced that Institutional Shareholder Services Inc.

Flex Pharma Reports First Quarter 2019 Financial Results

Flex Pharma Reports First Quarter 2019 Financial Results

Flex Pharma, Inc. (NASDAQ: FLKS), today announced its financial results for the three months ended March 31, 2019.

Flex Pharma Reports Fourth Quarter And Fiscal 2018 Financial Results

Flex Pharma Reports Fourth Quarter And Fiscal 2018 Financial Results

Flex Pharma, Inc. (NASDAQ: FLKS), today announced its financial results for the three months and fiscal year ended December 31, 2018.

Flex Pharma And Salarius Pharmaceuticals Announce Merger Agreement To Accelerate Clinical Development Of Novel Epigenetic Therapy For Cancer

Flex Pharma And Salarius Pharmaceuticals Announce Merger Agreement To Accelerate Clinical Development Of Novel Epigenetic Therapy For Cancer

Flex Pharma, Inc. (NASDAQ: FLKS), and Salarius Pharmaceuticals, LLC, a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that the companies have entered into a definitive merger agreement under which...

Flex Pharma Reports Third Quarter 2018 Financial Results

Flex Pharma Reports Third Quarter 2018 Financial Results

Flex Pharma, Inc. (NASDAQ: FLKS), today announced its financial results for the three months ended September 30, 2018.

Flex Pharma Reports Second Quarter 2018 Financial Results

Flex Pharma Reports Second Quarter 2018 Financial Results

Flex Pharma, Inc. (NASDAQ: FLKS), today announced its financial results for the three months ended June 30, 2018.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Flex Pharma, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Flex Pharma, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Flex Pharma, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Flex Pharma, Inc. Of Class Action Lawsuit And Upcoming Deadline- FLKS

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Flex Pharma, Inc. Of Class Action Lawsuit And Upcoming Deadline- FLKS

Pomerantz LLP announces that a class action lawsuit has been filed against Flex Pharma, Inc.

FLKS INVESTOR ALERT: Rosen Law Reminds Flex Pharma, Inc. Investors Of Important Deadline In Class Action - FLKS

FLKS INVESTOR ALERT: Rosen Law Reminds Flex Pharma, Inc. Investors Of Important Deadline In Class Action - FLKS

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Flex Pharma, Inc.

Robbins Arroyo LLP: Flex Pharma, Inc. (FLKS) Misled Shareholders According To A Recently Filed Class Action

Robbins Arroyo LLP: Flex Pharma, Inc. (FLKS) Misled Shareholders According To A Recently Filed Class Action

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Flex Pharma, Inc.

FLKS LOSS NOTICE: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Flex Pharma, Inc. - FLKS

FLKS LOSS NOTICE: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Flex Pharma, Inc. - FLKS

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Flex Pharma, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Flex Pharma, Inc. - FLKS

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Flex Pharma, Inc. - FLKS

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Flex Pharma, Inc.

Flex Pharma Announces Corporate Update

Flex Pharma Announces Corporate Update

Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company, today announced that the Company is ending its ongoing Phase 2 clinical trial investigations of FLX-787 in amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth (CMT) due to...

Flex Pharma Reports First Quarter 2018 Financial Results

Flex Pharma Reports First Quarter 2018 Financial Results

Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments in Phase 2 randomized, controlled trials for muscle cramps, spasms and spasticity associated with severe neurological...

Flex Pharma To Report First Quarter 2018 Financial Results On May 2, 2018

Flex Pharma To Report First Quarter 2018 Financial Results On May 2, 2018

Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases such as multiple sclerosis (MS), Charcot-Marie-Tooth...

Flex Pharma Reports Positive Topline Data From Exploratory Phase 2 Trial Of FLX-787 In Multiple Sclerosis

Flex Pharma Reports Positive Topline Data From Exploratory Phase 2 Trial Of FLX-787 In Multiple Sclerosis

Flex Pharma, Inc. (NASDAQ:FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps, spasms and spasticity associated with severe neurological diseases such as...

Flex Pharma Reports Year End 2017 Financial Results

Flex Pharma Reports Year End 2017 Financial Results

Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments in Phase 2 randomized, controlled trials for cramps and spasticity associated with...

Flex Pharma To Report Fourth Quarter And Full Year 2017 Results On March 7, 2018

Flex Pharma To Report Fourth Quarter And Full Year 2017 Results On March 7, 2018

Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe...

Flex Pharma Presenting At BIO CEO On February 13, 2018

Flex Pharma Presenting At BIO CEO On February 13, 2018

Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe...

Enrollment Completed In Flex Pharma's Phase 2 Exploratory Spasticity Study In MS

Enrollment Completed In Flex Pharma's Phase 2 Exploratory Spasticity Study In MS

Click to Tweet this News Flex Pharma, Inc.

Flex Pharma Reports Third Quarter 2017 Financial Results

Flex Pharma Reports Third Quarter 2017 Financial Results

Click to Tweet this News Flex Pharma, Inc.

Flex Pharma Reports Positive Topline Data From Exploratory Phase 2 Trial Of FLX-787 In ALS

Flex Pharma Reports Positive Topline Data From Exploratory Phase 2 Trial Of FLX-787 In ALS

Click to Tweet this News Flex Pharma, Inc.

Flex Pharma To Report Third Quarter 2017 Results On November 6, 2017

Flex Pharma To Report Third Quarter 2017 Results On November 6, 2017

Click to Tweet this News Flex Pharma, Inc.

Flex Pharma Names Dr. Roger Tung To Its Board Of Directors

Flex Pharma Names Dr. Roger Tung To Its Board Of Directors

Click to Tweet this News Flex Pharma, Inc.